IL6 and rheumatoid arthritis: In terms of targeting cytokines, for IL-6, trials of the anti-IL-6 receptor monoclonal antibody sarilumab in patients with rheumatoid arthritis (NCT04350216) and high CRP levels, and of the anti-IL-6 monoclonal antibody ziltivekimab in patients with chronic kidney disease and high CRP levels (NCT05021835) are ongoing, with the changes in atherosclerotic plaques and the incidence of MACE as the primary endpoints, respectively.